A number of firms have modified their ratings and price targets on shares of STERIS (NYSE: STE) recently:
- 8/9/2026 – STERIS was upgraded by Wall Street Zen from “hold” to “buy”.
- 8/7/2026 – STERIS had its price target lowered by UBS Group AG from $275.00 to $270.00. They now have a “buy” rating on the stock.
- 8/7/2026 – STERIS had its “overweight” rating reaffirmed by Piper Sandler. They now have a $275.00 price target on the stock, up from $270.00.
- 8/1/2026 – STERIS was downgraded by Wall Street Zen from “buy” to “hold”.
- 7/28/2026 – STERIS is now covered by UBS Group AG. They set a “buy” rating and a $275.00 price target on the stock.
- 7/28/2026 – STERIS is now covered by UBS Group AG. They set a “buy” rating and a $275.00 price target on the stock.
STERIS Increases Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 25th. Investors of record on Friday, September 4th will be given a $0.69 dividend. The ex-dividend date is Friday, September 4th. This represents a $2.76 annualized dividend and a dividend yield of 1.2%. This is a boost from STERIS’s previous quarterly dividend of $0.63. STERIS’s payout ratio is presently 30.81%.
Insider Buying and Selling at STERIS
In other STERIS news, Director Mohsen Sohi sold 4,058 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $235.78, for a total transaction of $956,795.24. Following the completion of the transaction, the director directly owned 24,305 shares in the company, valued at approximately $5,730,632.90. This trade represents a 14.31% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Daniel A. Carestio sold 1,374 shares of the firm’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $212.00, for a total transaction of $291,288.00. Following the transaction, the chief executive officer owned 63,647 shares of the company’s stock, valued at $13,493,164. This trade represents a 2.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 11,386 shares of company stock valued at $2,510,846 in the last quarter. Insiders own 1.12% of the company’s stock.
STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.
Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.
Featured Stories
- Five stocks we like better than STERIS
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
- D-Wave Has Momentum—What Does It Need to Keep It Going?
- TSMC’s Insider Buying Wave Comes With a Bigger AI Question for Investors
Receive News & Ratings for STERIS plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS plc and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.PNG){kind=logo}